Composition
Inj 10 mg/20 mg/50 mg: Per ml: Doxorubicin 2 mg; 10 mg(5 ml) & 20 mg(10 ml); 50 mg(25 ml); vial.
Indications & Dosage
Acute Lymphoblastic & Myeloblastic Leukaemia, Soft tissue and bone sarcomas, Breast carcinoma, Ovarian carcinoma, Lymphomas of both Hodgkin and non-Hodgkin type, Small cell lung cancer, Gastric carcinoma, Bladder carcinoma, Wilmstumour, Neuroblastoma, Bronchogenic, Thyroid carcinoma: BY IV INJ: Adult: Monotherapy: 60-75 mg/m2every 21 day. Combination therapy: 40-60 mg/m2every 21-28 days.
Administration
Administer IV push over 1-2 min or IVP Bolus. Infusion via central venous line recommended. Reconstitute lyophilized powder with NS to a final concentration of 2 mg/ml as follows. Further dilution in D5W or NS is stable for 48 hours at room temperature (25-C) when pro-tected from light. Unstable in solutions with a pH < 3 or > 7.Standard IV Dilution: IVP: Dose/syringe (concentration: 2 mg/ml). IVP Bolus: Dose 50-100 ml D5W or NS.
Compatibility
Stable in D5W, LR, NS.
Contraindications
Patients with marked myelosuppression, stomatitis.
Precautions
Cardiac failure. Hematological monitoring re-quired, Cardiac disease, caution in handling; irritant to tissues, elderly, hypertension, previous myocardial irradiation
Interactions
Heparin.
Pregnancy
Positive evidence of risk: Avoid
Lactation
Contraindicated. Discontinue breast-feeding
Side Effects
Dehydration, diarrhoea, red colouration of the urine, alopecia, bone-marrow suppression, cardiomyopathy (with higher cumulative doses), extravasation, heart failure, hyperuricaemia, nausea, oral mucositis, renal damage, thromboembolism, tumourlysis Syndrome, vomiting, elevated bilirubin concentration, supraventricular tachycardia,